E-18 Corp. Announces Availability of SmallcapInsights.com Article
MINNEAPOLIS-(Business Wire)-September 1, 2009 - E-18 Corp. (OTCBB: ETEN), through its wholly owned subsidiary, SquareOne Medical, Inc., doing business as Protectus Medical Devices ("Protectus Medical Devices"), today announces the release of a SmallcapInsights.com article by industry veteran, Dr. John Faessel.
Entitled “Launching: A Truly Unique ‘Safe Needle’”, Dr. Faessel guides readers through the enormous opportunity for the Protectus Safety Syringe as the sole safety syringe that automatically self-sheaths, potentially revolutionizing an important segment of the healthcare system. As a former healthcare professional himself, Dr. Faessel provides his unique insights and how the design could save hundreds of lives for those medical professionals at risk of contracting diseases through accidental needlesticks.
From the article:
“Over the 24+ years of my professional career as a health provider it's notable that during the injection procedure I have not only pricked myself several times, but several of my staff have also had the same ugly experience. In today's world of conditions such as hepatitis and HIV the worry after such an incident is horrifying due to the gravity of those blood-borne infections.”
Dr. Faessel goes on to say, “The patent protected Protectus Safety Syringe is the only safety syringe in existence today that meets all criteria of the federal mandate for safety syringes in the US, the self-sheathing criterion in particular. Importantly the syringe is fully compliant with federal and state laws and with the OSHA mandate.”
A link to this article is available on the SmallcapInsights.com website: http://www.smallcapinsights.com.
Announcing international patent protection status on August 27th, the Company's lead product, the Protectus Medical Safety Syringe, is an automatic, self-sheathing hypodermic safety syringe. The Protectus Medical Safety Syringe is designed to significantly reduce or eliminate accidental needlestick injuries that have plagued the healthcare workplace for decades. More information about Protectus Medical Devices may be found at the Company's corporate website at www.protectusmedical.com.
About E-18 Corp.
E-18 Corp., through its wholly owned subsidiary, SquareOne Medical, Inc., doing business as Protectus Medical Devices, develops and markets innovative safety medical percutaneous devices that, collectively, have the potential to dramatically reduce needlestick injuries for medical professionals worldwide. In the nearly $5 billion global hypodermic syringe market, the Protectus Safety Syringe, the Company's lead product, is the only fully automatic, self-sheathing hypodermic safety syringe that currently meets the functional definition of "Self-Sheathing" mandated by the U.S. Federal Government. None of the manufacturers of other devices on the market can make this claim. Protectus Medical Devices has successfully patented its automatic, self-sheathing hypodermic safety syringe product, and, based on the results of full comparison clinical trials, the Protectus Safety Syringe (formerly the SquareOne Safety Syringe) has received the required 510(k) permission from the U.S. FDA to manufacture and market the device in the U.S. More information about the Company may be found at www.protectusmedical.com.
Forward-Looking Statements
Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the Company's expectations with regard to the future impact on the Company's results from new products in development are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties. Words such as "expects," "intends," "plans," "may," "could," "should," "anticipates," "likely," "believes" and words of similar import also identify forward-looking statements. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Readers are urged not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Additional information on risks and other factors that may affect the business and financial results of E-18 Corp. can be found in the filings of E-18 Corp. with the U.S. Securities and Exchange Commission.
SEC Section 17(b) Disclosure: SmallcapInsights.com is a wholly owned subsidiary of Trilogy Capital Partners, Inc. (“Trilogy”). Trilogy has been engaged by E-18 Corp. ("ETEN") to provide investor relations services for compensation including a monthly retainer of $10,000 for an initial twelve month term and 450,000 shares of restricted common stock of ETEN, to be distributed in equal monthly installments over a six month period.
 |
 |
 |
|
||
 |
|
 |
|
||
Search Our News Using Google Search
Can't find what you want? Try using Google:
